Please assess the completion status of the following clinical trial:

Trial Title: The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women aged 18-75 year-old~2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2~3. Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph + CP-CML) within 6 months of diagnosis~4. Adequate organ function~Exclusion Criteria:~1. received TKIs drug treatment before enrollment~2. Central nervous system leukemia~3. Previous anti-CML therapy over two weeks (hydroxyurea, except anagrelide) or surgery (including hematopoietic stem cell transplantation)~4. Cardiac dysfunction~5. Previous splenectomy~6. History of congenital or acquired bleeding disorders unrelated to CML~7. Previous malignancy except CML~8. Acute or chronic liver or severe kidney disease unrelated to CML~9. Pregnant, breastfeeding, child bearing potential but failed to take effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Flumatinib mesylate tablets (Type: EXPERIMENTAL): Flumatinib mesylate tablets 600mg qd for 12 months
- Imatinib mesylate tablets (Type: ACTIVE_COMPARATOR): Imatinib mesylate tablets 400mg qd for 12months

Based on this trial design, predict the completion outcome and termination type (if applicable).